.jpeg)
2026-04-03 06:57:16
Deucravacitinib (brand name Sotyktu, Chinese trade name Songdiduo) is a next-generation, oral, highly selective TYK2 inhibitor developed for the pathological mechanism of psoriasis. Approved in multiple countries and regions worldwide for the systemic treatment of adults with moderate-to-severe plaque psoriasis, it precisely modulates inflammatory pathways to improve skin lesions, with the advantages of rapid onset, durable long-term efficacy, and convenient oral administration, providing a non-injectable, non-biologic treatment option for patients with psoriasis.
2026-04-03 06:50:04
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a next-generation fixed-dose combination (FDC) antiretroviral therapy for HIV. It features minimal food dependence, with consistent absorption and antiviral efficacy whether taken with or without food. The core clinical principle is consistent daily dosing at a fixed time to maintain long-term viral suppression.
2026-04-03 06:26:16
Valganciclovir (Valcyte) is a core antiviral for CMV prevention and treatment in transplant and immunocompromised patients. Its duration is individualized based on immune status, transplant type, virologic monitoring, and risk stratification, balancing efficacy and safety against myelosuppression.
2026-04-03 06:19:35
Cabergoline is a highly selective long-acting dopamine D2 receptor agonist, the first-line treatment for hyperprolactinemia (HPRL), pituitary prolactinoma, and physiological lactation suppression. Its core clinical dosing strategy follows low-dose initiation with gradual individualized titration. This article details its full clinical specifications, including dosing regimens, dose adjustment principles, indication-specific treatment duration, and post-discontinuation monitoring.
2026-04-03 06:00:38
Rucaparib (brand name Rubraca) is a highly selective oral PARP inhibitor, granted full regular approval by the U.S. FDA on December 17, 2025, for the treatment of adult patients with deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval is based on pivotal data from the phase III TRITON3 trial, marking the conversion from accelerated approval to full approval, and providing a new precision targeted therapy option for patients with advanced prostate cancer.
2026-04-03 01:52:29
Adagrasib (brand name Krazati) is a highly selective oral KRAS G12C inhibitor, approved by the U.S. FDA for the treatment of KRAS G12C-mutated locally advanced/metastatic non-small cell lung cancer and colorectal cancer. It features excellent blood-brain barrier penetration and a long half-life, providing a precise anti-tumor option for patients with advanced solid tumors.
2026-04-02 05:08:01
This article provides a comprehensive analysis of the pharmacological effects, indicated populations, correct administration methods, contraindications, and medication safety precautions of aspirin enteric-coated tablets, offering standardized medication reference for populations at risk of cardiovascular and cerebrovascular diseases.
2026-04-01 04:22:07
Osimertinib (brand names Tagrisso/Tarceva), developed by AstraZeneca (UK), is a third-generation EGFR-TKI that selectively inhibits EGFR T790M, L858R, and exon 19 deletion mutations to block cancer cell signaling. It is widely used for EGFR-mutant non-small cell lung cancer (NSCLC).
2026-04-01 04:06:04
Published in The New England Journal of Medicineon March 25, 2026, the ATOMIC study by Dr. Frank A. Sinicrope’s team at Mayo Clinic demonstrated that atezolizumab combined with mFOLFOX6 chemotherapy significantly extended disease-free survival (DFS) in patients with dMMR stage III colon cancer, providing key evidence for immunotherapy applicability in this population.
2026-04-01 02:55:09
On April 1, 2026, the U.S. FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), indicated for pediatric patients with biallelic ITGB2 variants and no available HLA-matched sibling donor for allogeneic hematopoietic stem cell transplantation.
2026-04-01 02:16:12
Cancer cells act as "rebellious agents" disrupting bodily harmony. Through global research advancements, we uncover the mechanisms of cancer formation, differences in types, and innovative therapies. From surgical removal to immunotherapy, scientific progress offers new hope. Dive into the mysteries of cancer and its future treatment prospects.
2026-03-31 02:36:04
This article dissects the fundamental differences between Dostarlimab (PD-1 inhibitor) and Secukinumab (IL-17A antagonist) across mechanisms, indications, efficacy metrics, and safety profiles, emphasizing their distinct roles in oncology and autoimmune diseases.
